Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928629" target="_blank" >RIV/00064173:_____/25:43928629 - isvavai.cz</a>

Alternative codes found

RIV/60460709:41210/25:101903 RIV/00216208:11120/25:43928629

Result on the web

<a href="https://doi.org/10.3390/cancers17132238" target="_blank" >https://doi.org/10.3390/cancers17132238</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers17132238" target="_blank" >10.3390/cancers17132238</a>

Result language

angličtina

Original language name

Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma

Original language description

The oral microbiome is the largest and most diverse microbiome in the human body, second only to the gut microbiome. Mounting evidence supports its role in the genesis, promotion, and aggressiveness of oral cancer as well as certain cancers of distant sites. In this review, we focus on describing specific microbial alterations, which were proven to be associated either with head and neck squamous cell carcinoma (HNSCC) development or with its treatment efficacy, especially with radiotherapy, chemotherapy, targeted treatment, and immunotherapy. Purpose: To discuss associations of oral and gut microbiome with the development of HNSCC and with its anti-cancer treatment efficacy. Methods: A literature search was conducted in PubMed/Medline. Due to the nature of this narrative review, we prioritized the most recent studies. Regarding the type of studies, umbrella reviews, meta-analyses, and systematic reviews were prioritized, in that order, over individual studies. Results: The microbiome plays an important role in cancer development, progression, and treatment response across solid tumors, including HNSCC. Better treatment response and/or reduction in treatment toxicities can be achieved through microbiome alteration; e.g., the use of specific probiotics can result in a reduction in acute radiotherapy-induced mucositis in HNSCC radiotherapy, and fecal microbiota transplantation from immune-checkpoint inhibitor (ICI) responders to non-responders can overcome primary resistance to ICI. Conclusions: We highlighted specific research areas on how to utilize microbiome modification to enhance anti-cancer treatment response and/or decrease the incidence and severity of anti-cancer treatment toxicities.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancers

ISSN

2072-6694

e-ISSN

2072-6694

Volume of the periodical

17

Issue of the periodical within the volume

13

Country of publishing house

CH - SWITZERLAND

Number of pages

30

Pages from-to

2238

UT code for WoS article

001526122100001

EID of the result in the Scopus database

2-s2.0-105010619106